++
“I can’t go anywhere without wearing a pad, and the smell can be embarrassing.”
+++
History of Present Illness
++
BW is a 76-year-old female with complaints of urinary incontinence. Her friend told her that Vesicare has helped her symptoms a lot, and BW is interested in trying it.
++
++
++
What type of urinary incontinence is BW experiencing? What led you to that conclusion?
Hint: See Pathophysiology in PPP
What are some of BW’s risk factors for urinary incontinence?
Hint: See Pathophysiology in PPP
What medication(s) may be exacerbating BW’s symptoms of incontinence? How do you suggest addressing this/these issue(s)?
Hint: See Table 53-1 in PPP
Do you initiate solifenacin (Vesicare) today? Why or why not?
Hint: See Table 53-3 and 53-5 in PPP
What non-pharmacologic recommendations do you have today to improve her symptoms?
Hint: See Treatment in PPP
++
3 months later, BW returns to your clinic and notes that the non-pharmacologic interventions you recommended at her last visit have not helped. She insists on starting pharmacologic therapy. What would you like to try today?
++
Hint: See table 53-5 in PPP
++
Urinary incontinence (UI) is a global issue that disproportionately impacts women, from young girls in developing countries experiencing post-partum UI to postmenopausal women experiencing urge or stress incontinence. Unfortunately, UI is often accompanied by shame, embarrassment, and reluctance to seek treatment across many cultures and countries. While patients are oftentimes requesting pharmacologic therapy by the time they seek treatment for UI, it is important to first determine the type of incontinence causing the symptoms. In many cases, medications with adverse side effect profiles (e.g., antimuscarinic drugs) are initiated when they are not indicated or where non-pharmacologic therapy should be attempted first.
1. +
Staskin
D, Frankel
J, Varano
S, Shortino
D, Jankowich
R, Mudd
PN. International phase iii, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: empowur. J Urol. 2020;204(2):316–324.
[PubMed: 32068484]
2. +
Hu
JS, Pierre
EF. Urinary incontinence in women: evaluation and management. Am Fam Physician. 2019;100(6):339–348.
[PubMed: 31524367]
3. +
Lightner
DJ, Gomelsky
A, Souter
L
et al: Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU Guideline amendment 2019. J Urol 2019; 202: 558.
[PubMed: 31039103]
4. +
Gormley
EA, Lightner
DJ, Burgio
KL
...